EN | TR
E-ISSN: 2602-2974
Carbapenem Resistance Profile of <i>Acinetobacter baumannii</i> Complex Strains in the Intensive Care Unit of a University Hospital in Northern Cyprus: 3-Year Follow-up
PDF
Cite
Share
Request
Original Research
VOLUME: 19 ISSUE: 3
P: 118-122
September 2021

Carbapenem Resistance Profile of Acinetobacter baumannii Complex Strains in the Intensive Care Unit of a University Hospital in Northern Cyprus: 3-Year Follow-up

J Turk Soc Intens Care 2021;19(3):118-122
DOI: 10.4274/tybd.galenos.2019.72324
Meryem Güvenir 1
Emrah Güler 2
Kaya Süer 3
1. Yakın Doğu Üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu, Mikrobiyoloji Bölümü, Lefkoşa, KKTC
2. Yakın Doğu Üniversitesi, Sağlık Hizmetleri Meslek Yüksekokulu, Mikrobiyoloji Anabilim Dalı, Lefkoşa, KKTC
3. Yakın Doğu Üniversitesi, Tıp Fakültesi, Tıbbi ve Klinik Mikrobiyoloji Anabilim Dalı, Lefkoşa, KKTC
4. Yakın Doğu Üniversitesi, Tıp Fakültesi, İnfeksiyon Hastalıkları Ve Klinik Mikrobiyoloji Anabilim Dalı, Lefkoşa, Kktc
5. Yakın Doğu Üniversitesi Tıp Fakültesi, Tıbbi ve Klinik Mikrobiyoloji Anabilim Dalı, Lefkoşa, KKTC
6. Yakın Doğu Üniversitesi Tıp Fakültesi, Enfeksiyon Hastalıkları ve Klinik Mikrobiyoloji Anabilim Dalı, Lefkoşa, KKTC
No information available.
No information available
Received Date: 24.09.2019
Accepted Date: 18.11.2019
Publish Date: 26.08.2021
PDF
Cite
Share
Request

ABSTRACT

Objective:

This study aimed to investigate the distribution of three-year carbapenem resistance of Acinetobacter baumannii complex (ABC) in hospital infections isolated from the intensive care unit in the last three years.

Materials and Methods:

The patients who had ABC infection in the Intensive Care Unit of Near East University Hospital between 2016-2018 were included in this study. The data of the patients were investigated retrospectively from the digital records and the Infection Control Committee data. The initial infection report of the patients who had multiple ABC infections was included in the study. SPSS Statistics 23.0 program was used for statistical analysis.

Results:

A total of 92 patients were diagnosed with ABC infection during the study period, including 22 (23.9%) in 2016, 31 (33.7%) in 2017 and 39 (42.4%) in 2018. Fifty-six patients (60.9%) were male and 36 (39.1%) were female. The mean age of the patients was 61.61±17.43 years (range, 22-89 years). The most common isolates were from tracheal aspirate (28.3%, 26 patients), sputum 27.2%, 25 patients) and urine samples (23.9%, 22 patients). Carbapenem-resistant ABC infection was detected in 65 patients (70.7%) and carbapenemsensitive ABC infection was found in 27 patients (29.3%). There was a statistically significant increase in carbapenem-resistant ABC strains over the years (p<0.05, p=0.012). Thirty-one of the 38 carbapenem-resistant patients were dead.

Conclusion:

ABC strains that cause high mortality infections can develop resistance to many antibiotic groups very quickly. Therefore, fatality due to multiple antibiotic-resistant ABC strains is increasing all over the world. It was seen that ABC infections had increased in our hospital over years. In parallel, there was a statistically significant increase in carbapenem-resistant ABC strains. Nowadays, it is essential to ensure proper application of isolation rules, to provide relevant personnel training and to prevent ABC infections with rational antibiotic use.

Keywords: Acinetobacter baumanii complex, antimicrobial resistance, intensive care unit

References

1
Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48:1-12.
2
Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010;35:219-26.
3
Acinetobacter. Us AD, Başustaoğlu A, çeviri editörleri. İçinde: Murray PR, Rosenthal KS, Pfaller MA, editörler. Tıbbi Mikrobiyoloji. 6. baskı. Pelikan Kitabevi; 2016.
4
Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 2008;21:538-82.
5
Turton JF, Ward ME, Woodford N, Kaufmann ME, Pike R, Livermore DM, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006;258:72-7.
6
Figueiredo S, Poirel L, Papa A, Koulourida V, Nordmann P. Overexpression of the naturally occurring blaOXA-51 gene in Acinetobacter baumannii mediated by novel insertion sequence ISAba9. Antimicrob Agents Chemother 2009;53:4045-7.
7
Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob Agents Chemother 2007;51:4022-8.
8
Zarrilli R, Giannouli M, Tomasone F, Triassi M, Tsakris A. Carbapenem resistance in Acinetobacter baumannii: the molecular epidemic features of an emerging problem in health care facilities. J Infect Dev Ctries 2009;3:335-41.
9
Deveci A, Coban AY, Acicbe O, Tanyel E, Yaman G, Durupinar B. In vitro effects of sulbactam combinations with different antibiotic groups against clinical Acinetobacter baumannii isolates. J Chemother 2012;24:247-52.
10
Garnacho-Montero J, Ortiz-Leyba C, Fernández-Hinojosa E, Aldabó-Pallás T, Cayuela A, Marquez-Vácaro JA, et al. Acinetobacter baumannii ventilator-associated pneumonia: epidemiological and clinical findings. Intensive Care Med 2005;31:649-55.
11
García-Garmendia JL, Ortiz-Leyba C, Garnacho-Montero J, Jiménez-Jiménez FJ, Pérez-Paredes C, Barrero-Almodóvar AE, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: a cohort study. Clin Infect Dis 2001;33:939-46.
12
Leung WS, Chu CM, Tsang KY, Lo FH, Lo KF, Ho PL. Fulminant community-acquired Acinetobacter baumannii pneumonia as a distinct clinical syndrome. Chest 2006;129:102-9.
13
Balcı M, Bitirgen M, Kandemir B, Arıbas E. Selçuk Üniversitesi Meram Tıp Fakültesi, Klinik Bakteriyoloji ve Enfeksiyon Hastalıkları Anabilim Dalı, Konya 2. EKMUD Kongresi, 2008.
14
Bayram Y, Gültepe B, Bektaş A, Parlak M, Güdücüoğlu H. Çeşitli klinik örneklerden izole edilen Acinetobacter baumanii suşlarının Antibiyotiklere Direnç Oranlarının Araştırılması. Klimik Dergisi 2013;26:49-53.
15
Erben N, Kiremitçi A, Özgünes İ. Klinik örneklerden izole edilen Acinetobacter türlerinde genisletilmis spektrumlu beta-laktamaz ve indüklenebilir beta-laktamaz sıklıgının ve antimikrobiyal duyarlılıgın degerlendirilmesi. Osmangazi Tıp Dergisi 2006;28:135-46.
16
Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW, et al. A multicenter study of risk factors and outcome of hospitalized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Int J Infect Dis 2010;14:e764-9.
17
Uğur M, Genç S. Yoğun Bakım Ünitelerinden İzole edilen Ainetobacter baumannii ve Pseudomonas aeruginosa Suşlarının Üç Yıllık Direnç Profili. Turk J Intensive Care 2019; 17:130-7.
18
Ruh E, Gazi U, Guvenir M, Süer K, Cakır N. Antibiotic resistance rates of Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae isolated from a university-affiliated hospital in North Cyprus. Turk Hij Den Biyol Derg 2016;73:333-44.
19
Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344:1329-32.
20
Urban C, Go E, Mariano N, Berger BJ, Avraham I, Rubin D, et al. Effect of sulbactam on infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis 1993;167:448-51.
21
Fishbain J, Peleg AY. Treatment of Acinetobacter infections. Clin Infect Dis 2010;51:79-84.
22
CAESAR-2018. Erişim Linki: euro.who.int/_data/assets/pdf_file/0007/386161/52238-WHO-CAESAR-AR-2018_low_V11_web.pdf
23
Surveillance of antimicrobial resistance in Europe. 2017. Erişim Linki: https://www.ecdc.europa.eu/sites/portal/files/documents/AMR-surveillance-EARS-Net-2017.pdf
24
Ulusal Antimikrobiyal Direnç Sürveyans Sistemi, 2016. Erişim Linki: https://hsgm.saglik.gov.tr/depo/birimler/Mikrobiyoloji_Referans_Laboratuvarlari_ve_Biyolojik_Urunler_DB/uamdss/yillik_raporlar/UAMDSS_2016_Rapor.pdf
25
Eroğlu G, Unal N, Karadağ A, Yılmaz H, Acuner İC, Gunaydın M. Ceşitli klinik orneklerden 2006-2011 yılları arasında izole edilen Acinetobacter turleri ve antibiyotik duyarlılıkları. Turk Hij Den Biyol Derg 2016;73:25-32.
26
Şay Çoşkun US. Karbapenem dirençli Acınetobacter baumanıı izolatlarında antibiyotik direncinin araştırılması. ANKEM Derg 2018;32:37-44.
27
Dede B, Kadanalı A, Karagöz G, Çomoğlu Ş, Bektaşoğlu MF, Yücel FM. Yoğun bakım ünitesinde izole edilen Acinetobacter baumanii suşlarının antibiyotik dirençlerinin araştırılması. Bakırköy Tıp Dergisi 2013;9:20-3.
2024 ©️ Galenos Publishing House